The European Commission (EC) has approved Forxiga (dapagliflozin) for use in Type 1 diabetes (T1D) as an adjunct to insulin in patients with a BMI
Type 1 diabetic Rob Brown has set off for Morocco where he is taking part in the Marathon des Sables, a 150-mile footrace across the
Novo Nordisk UK has announced that Ozempic (semaglutide), a new once-weekly GLP-1 analogue injection for the treatment of Type 2 diabetes is now available in
One in ten people over 40 in the UK is now living with a diagnosis of Type 2 diabetes, according to new analysis released by
Marking the start of NHS England’s Type 2 Diabetes Prevention Week, Diabetes UK has released new analysis which shows that one person is diagnosed with
The administrators appointed at Cellnovo Ltd., the Cellnovo Group (“Cellnovo” or the “Company”)’s UK subsidiary, have concluded an initial analysis and have actioned a restructuring
Those of us on insulin pumps must wait four years between each pump change, but Animas users were forced to change sooner than that when
Cellnovo Group SA, having announced that it is facing a delay in the large-scale commercial deployment of its new insulin infusion solution, needed to find
Time to get ready Britain. Take part in the national On Your Feet Day when workers across UK will unite together and participate in a
The new Amplify Life app combines tech with fitness for a one-stop solution. The app uses AI and data uploaded from your devices, to deliver
